STUDY AIM: To identify prognostic factors in advanced pancreatic cancer and to define a predictive score. PATIENTS AND METHOD: One hundred and sixty six patients were included in this multicentre study. Seventeen covariables were prospectively collected for each patient. Covariables associated with survival (p < 0.10) were analysed by a stepwise Cox model. RESULTS: Four prognostic factors were selected on multivariate analysis: pain (RR 1.5; CI: 1.1-2.0), ascites (RR 1.7; CI: 1.0-2.9), weight loss > 10 kg (RR 1.4; CI: 1.0-2.0), and metastases (RR 2.3: CI: 1.6-3.2). A score was defined by attributing a value of one for pain, ascites and weight loss, and two for metastases. Patients with a score > 2 had a median survival of 2 months (SE: 0.5), and patients with a score < or = 2 had a median survival of 6 months (SE: 0.6) (Logrank p < 0.0001). CONCLUSION: The proposed score may be helpful in therapeutic decisions concerning surgery, palliative chemotherapy and/or radiotherapy. However, this score must be validated on an independent series of patients.
STUDY AIM: To identify prognostic factors in advanced pancreatic cancer and to define a predictive score. PATIENTS AND METHOD: One hundred and sixty six patients were included in this multicentre study. Seventeen covariables were prospectively collected for each patient. Covariables associated with survival (p < 0.10) were analysed by a stepwise Cox model. RESULTS: Four prognostic factors were selected on multivariate analysis: pain (RR 1.5; CI: 1.1-2.0), ascites (RR 1.7; CI: 1.0-2.9), weight loss > 10 kg (RR 1.4; CI: 1.0-2.0), and metastases (RR 2.3: CI: 1.6-3.2). A score was defined by attributing a value of one for pain, ascites and weight loss, and two for metastases. Patients with a score > 2 had a median survival of 2 months (SE: 0.5), and patients with a score < or = 2 had a median survival of 6 months (SE: 0.6) (Logrank p < 0.0001). CONCLUSION: The proposed score may be helpful in therapeutic decisions concerning surgery, palliative chemotherapy and/or radiotherapy. However, this score must be validated on an independent series of patients.
Authors: Phillip J Gray; Jingya Wang; Timothy M Pawlik; Barish H Edil; Richard Schulick; Ralph H Hruban; Harry Dao; John Cameron; Christopher Wolfgang; Joseph M Herman Journal: J Surg Oncol Date: 2012-02-03 Impact factor: 3.454
Authors: Rosalie A Carr; Alexandra M Roch; Xin Zhong; Eugene P Ceppa; Nicholas J Zyromski; Attila Nakeeb; C Max Schmidt; Michael G House Journal: J Gastrointest Surg Date: 2017-08-07 Impact factor: 3.452
Authors: Emmanuel E Zervos; Dana Osborne; Brian A Boe; German Luzardo; Steven B Goldin; Alexander S Rosemurgy Journal: World J Surg Oncol Date: 2006-03-28 Impact factor: 2.754
Authors: D D Stocken; A B Hassan; D G Altman; L J Billingham; S R Bramhall; P J Johnson; N Freemantle Journal: Br J Cancer Date: 2008-09-16 Impact factor: 7.640